Innovent Biologics (HK:1801) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Innovent Biologics has decided to terminate its proposed subscription agreement with Fortvita and Lostrancos after receiving feedback from shareholders. The company remains committed to its strategic objectives and aims to focus on long-term international growth, believing that the termination is in the best interest of shareholders.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.